I still don't understand why, if this is such a seismic development for Amarin, management has said literally nothing about it.
Is there a reason to stay utterly silent on this. Prior management certainly talked about the combo pill...
Incidentally, I checked the Recordati agreement -- it appears to cover any new "formulation"...
1.48“Licensed Product” means the pharmaceutical product marketed under the trade name Vazkepa® and other associated Trademarks containing or comprising the compound Icosapent ethyl in any present or future finished form presentations (including all dosage forms, formulations, dosage strengths and packaging configurations).